Solutions
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Inquiry

Epigenetic Reader Domain

Epigenetic Reader Domain

Epigenetic regulators play a crucial role in controlling gene expression and modifying the chromatin state. These regulators can be categorized as "writers", "erasers", and "readers" of chromatin modifications. Readers are known for their specific domain interactions with modified chromatin. For instance, bromodomains are commonly associated with acetyllysine binding, while chromo, malignant brain tumor (MBT), plant homeodomain (PHD), and Tudor domains are often associated with methyllysine recognition.

The identification of selective inhibitors targeting bromodomains, such as the bromodomain and extra terminal motif (BET) family, has greatly advanced the field of epigenetic reader research. Notably, the human genome contains 46 proteins with a total of 61 bromodomains grouped into eight families.

For more details about our epigenetic reader domain products, please click the links listed below.

  • AT9283
  • CAT#:

    DEERD-2312-LGZ-2

  • CAS Number:

    896466-04-9

  • Application:

    Aurora/JAK Inhibitor

  • CUDC-101
  • CAT#:

    DEERD-2312-LGZ-3

  • CAS Number:

    1012054-59-9

  • Application:

    HDAC Inhibitor

  • PF-03814735
  • CAT#:

    DEERD-2312-LGZ-4

  • CAS Number:

    942487-16-3

  • Application:

    Aurora A/B Kinase Inhibitor

  • BET-IN-1
  • CAT#:

    DEERD-2312-LGZ-7

  • CAS Number:

    1422554-34-4

  • Application:

    Bromodomain Inhibitor

  • Tenovin-6
  • CAT#:

    DEERD-2312-LGZ-8

  • CAS Number:

    1011557-82-6

  • Application:

    p53 Activator

  • GSK9311
  • CAT#:

    DEERD-2312-LGZ-9

  • CAS Number:

    1923851-49-3

  • Application:

    Inhibitor of the BRPF Bromodomain

  • GNE-272
  • CAT#:

    DEERD-2312-LGZ-10

  • CAS Number:

    1936428-93-1

  • Application:

    CBP/EP300 Inhibitor

Copyright © Protheragen. All rights reserves.